Trikafta annual cost?

What is the typical annual cost of Trikafta in the US?

The annual cost of Trikafta, a cystic fibrosis medication developed by Vertex Pharmaceuticals, can vary depending on several factors, such as insurance coverage, dosage, and patient eligibility for assistance programs [1]. According to data available on DrugPatentWatch.com, the list price of Trikafta is around $295,000 per year, although actual prices paid by patients and payers may differ due to discounts, rebates, and other factors [2].

How do prices compare to other cystic fibrosis treatments?

Trikafta is generally priced higher than other cystic fibrosis medications, including Kalydeco (ivacaftor), Orkambi (lumacaftor-ivacaftor), and SYMDEKO (tezacaftor-ivacaftor) [3]. However, its efficacy and potential to slow disease progression may justify the higher cost for some patients [4].

Are there assistance programs available to help with the cost?

Yes, Vertex Pharmaceuticals offers several assistance programs to help patients cover the cost of Trikafta, including the Vertex Patient Assistance Program (VPAP) and the Cystic Fibrosis Community Assistance Program (CF CAP) [5]. These programs can provide financial assistance, free medication, and access to other support services.

How long will the patent on Trikafta last?

The patent on Trikafta, also known as elexacaftor-ivacaftor-tezacaftor, is set to expire in 2033 [6]. However, generic versions of the medication may not become available until 2034, assuming a standard 5-year regulatory review period and no delays.

Sources:
[1] Vertex Pharmaceuticals. (2022). Trikafta (elexacaftor-ivacaftor-tezacaftor) Prescribing Information.
[2] DrugPatentWatch.com. (2022). Trikafta Patent Expiration Date.
[3] US National Library of Medicine. (2022). Cystic Fibrosis Medications.
[4] Cystic Fibrosis Foundation. (2022). Trikafta.
[5] Vertex Pharmaceuticals. (2022). Patient Assistance Programs.
[6] Lex Machina. (2022). Trikafta Patent Overview.